What is Talphera?
Headquartered in San Mateo, California, Talphera, Inc. operates as a specialty pharmaceutical entity dedicated to the development and commercialization of innovative therapies designed for use in controlled, medically supervised settings. Formerly known as AcelRx Pharmaceuticals, the company rebranded in early 2024 to better align with its evolving strategic focus on acute care and hospital-based interventions.
The company's core portfolio is anchored by Niyad, a lyophilized formulation of nafamostat currently under investigation as an anticoagulant for extracorporeal circuits. Beyond its lead candidate, Talphera is actively exploring the therapeutic potential of LTX-608, an anti-inflammatory and antiviral agent targeting complex conditions such as acute respiratory distress syndrome and disseminated intravascular coagulation. Additionally, the firm maintains a robust pipeline of pre-filled syringe products, including Fedsyra and PFS-02, which are engineered to enhance clinical efficiency and safety in high-acuity care environments.
How much funding has Talphera raised?
Talphera has raised a total of $46M across 2 funding rounds:
Stock/Share Issuance
$29M
Private Equity
$17M
Stock/Share Issuance (2025): $29M, investors not publicly disclosed
Private Equity (2025): $17M, investors not publicly disclosed
Key Investors in Talphera
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Talphera?
Looking ahead, Talphera is positioned to leverage its recent capital injection to accelerate the clinical development and regulatory submission processes for its primary assets. The strategic priority remains the successful advancement of Niyad through the investigational device exemption pathway, a critical step for establishing a foothold in the anticoagulant market. Furthermore, the company is expected to focus on the operational scaling of its pre-filled syringe portfolio, which addresses the growing demand for standardized, ready-to-use medications in hospital settings.
Investors will likely monitor the progress of LTX-608, as its potential to treat multi-system inflammatory conditions represents a significant value-creation opportunity. By maintaining a disciplined approach to research and development, Talphera aims to solidify its reputation as a key player in the specialty pharmaceutical sector, balancing its existing commercial offerings with a high-potential pipeline of next-generation therapies.
